{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:38:19Z","timestamp":1792478299027,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cppah.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Pediatric and Adolescent Health Care"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.cppeds.2016.04.003","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T14:02:15Z","timestamp":1465221735000},"page":"229-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Progress and Prospects in Pediatric Leukemia"],"prefix":"10.1016","volume":"46","author":[{"given":"P. Pallavi","family":"Madhusoodhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teena","family":"Bhatla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cppeds.2016.04.003_bib1","series-title":"Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975\u20131995","author":"Ries LAG","year":"1999"},{"issue":"4","key":"10.1016\/j.cppeds.2016.04.003_bib2","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1542\/peds.2013-3926","article-title":"Cancer incidence rates and trends among children and adolescents in the United States, 2001\u20132009","volume":"134","author":"Siegel","year":"2014","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.cppeds.2016.04.003_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics","volume":"64","author":"Ward","year":"2014","journal-title":"Cancer J Clin"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood.V75.1.174.174","article-title":"Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia","volume":"75","author":"Pui","year":"1990","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cppeds.2016.04.003_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(00)00435-6","article-title":"Pattern of malignant disorders in individuals with Down\u2019s syndrome","volume":"2","author":"Hasle","year":"2001","journal-title":"Lancet Oncol"},{"issue":"9199","key":"10.1016\/j.cppeds.2016.04.003_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","article-title":"Risks of leukaemia and solid tumours in individuals with Down\u2019s syndrome","volume":"355","author":"Hasle","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cppeds.2016.04.003_bib7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia","volume":"45","author":"Holmfeldt","year":"2013","journal-title":"Nat Genet"},{"issue":"26","key":"10.1016\/j.cppeds.2016.04.003_bib8","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2014-12-580001","article-title":"Inherited genetic variation in childhood acute lymphoblastic leukemia","volume":"125","author":"Moriyama","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cppeds.2016.04.003_bib9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/gcc.20671","article-title":"High hyperdiploid childhood acute lymphoblastic leukemia","volume":"48","author":"Paulsson","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"issue":"13","key":"10.1016\/j.cppeds.2016.04.003_bib10","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1182\/blood-2012-06-437681","article-title":"Hyperdiploidy with 58\u201366 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results","volume":"121","author":"Dastugue","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cppeds.2016.04.003_bib11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cppeds.2016.04.003_bib12","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2006-01-024729","article-title":"Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children\u2019s Cancer Group (CCG)","volume":"109","author":"Schultz","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cppeds.2016.04.003_bib13","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood-2014-08-569228","article-title":"Blood Spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease","volume":"125","author":"Harrison","year":"2015","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.cppeds.2016.04.003_bib14","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1200\/JCO.2010.30.1325","article-title":"Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005","volume":"28","author":"Arico","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.cppeds.2016.04.003_bib15","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children\u2019s Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.cppeds.2016.04.003_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11899-009-0023-4","article-title":"Infant acute lymphoblastic leukemia: Lessons learned and future directions","volume":"4","author":"Pieters","year":"2009","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jpeds.2011.08.006","article-title":"Clinical and laboratory biology of childhood acute lymphoblastic leukemia","volume":"160","author":"Carroll","year":"2012","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.cppeds.2016.04.003_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.cppeds.2016.04.003_bib19","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.V72.6.1891.1891","article-title":"Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group Study","volume":"72","author":"Crist","year":"1988","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V25.1.1.1","article-title":"Central nervous system involvement by leukemia in children. I. Relationship to systemic leukemia and description of clinical and laboratory manifestations","volume":"25","author":"Hyman","year":"1965","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cppeds.2016.04.003_bib21","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/1097-0142(197504)35:4<1203::AID-CNCR2820350426>3.0.CO;2-3","article-title":"Extramedullary involvement of the testes in childhood leukemia","volume":"35","author":"Stoffel","year":"1975","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.cppeds.2016.04.003_bib22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1470-2045(00)00418-6","article-title":"Minimal residual disease in leukaemia patients","volume":"2","author":"Szczepanski","year":"2001","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.cppeds.2016.04.003_bib23","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cppeds.2016.04.003_bib24","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cppeds.2016.04.003_bib25","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.cppeds.2016.04.003_bib26","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.cppeds.2016.04.003_bib27","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1182\/blood-2014-11-551481","article-title":"How I treat acute lymphoblastic leukemia in older adolescents and young adults","volume":"125","author":"Curran","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cppeds.2016.04.003_bib28","doi-asserted-by":"crossref","unstructured":"Larsen E, Raetz EA, Winicj NJ, et al. Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B precursor acute lymphoblastic leukemia (HR-ALL): A report from the Children\u2019s Oncology Group study AALL0232. 2012 ASCO Annual Meeting. Chicago, USA; 2012.","DOI":"10.1200\/jco.2012.30.18_suppl.cra9508"},{"key":"10.1016\/j.cppeds.2016.04.003_bib29","doi-asserted-by":"crossref","unstructured":"Advani AS, Sanford B, Luger SM. et al. Frontline-treatment of acute lymphoblastic leukemia (ALL) In older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective U.S. Intergroup Trial C10403 (Alliance). 55th Annual ASH Meeting and Exposition. New Orleans, USA; 2013.","DOI":"10.1182\/blood.V122.21.3903.3903"},{"key":"10.1016\/j.cppeds.2016.04.003_bib30","doi-asserted-by":"crossref","unstructured":"Stock W, Luger SM, Advani AS. et al. Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of U.S. Intergroup Trial C10403. 56th Annual ASH Meeting and Exposition. San Fransisco, CA, USA; 2014.","DOI":"10.1182\/blood.V124.21.796.796"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/asheducation-2010.1.363","article-title":"Pediatric acute lymphoblastic leukemia: is there still a role for transplant?","author":"Davies","year":"2010","journal-title":"Hematology, The Education Program of the American Society of Hematology"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/asheducation.V2012.1.129.3800156","article-title":"Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?","author":"Raetz","year":"2012","journal-title":"Hematology, The Education Program of the American Society of Hematology"},{"issue":"5906","key":"10.1016\/j.cppeds.2016.04.003_bib33","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1126\/science.1164266","article-title":"Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia","volume":"322","author":"Mullighan","year":"2008","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.cppeds.2016.04.003_bib34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MPH.0000000000000179","article-title":"The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions","volume":"36","author":"Bhatla","year":"2014","journal-title":"J Pediatr Hematol\/Oncol"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjh.13011","article-title":"Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia","volume":"167","author":"Dandekar","year":"2014","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.cppeds.2016.04.003_bib36","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood-2015-04-639138","article-title":"MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia","volume":"126","author":"Jones","year":"2015","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.cppeds.2016.04.003_bib37","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1182\/blood-2011-04-345595","article-title":"Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies","volume":"118","author":"Hogan","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.cppeds.2016.04.003_bib38","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1182\/blood-2012-01-401687","article-title":"Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia","volume":"119","author":"Bhatla","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cppeds.2016.04.003_bib39","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/ajh.23778","article-title":"A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"89","author":"Burke","year":"2014","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.cppeds.2016.04.003_bib40","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.cppeds.2016.04.003_bib41","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.cppeds.2016.04.003_bib42","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001\u20132007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cppeds.2016.04.003_bib44","series-title":"SEER Cancer Statistics Review, 1975\u20132012","author":"Howlader","year":"2015"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng955","article-title":"Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome","volume":"32","author":"Wechsler","year":"2002","journal-title":"Nat Genet"},{"issue":"26","key":"10.1016\/j.cppeds.2016.04.003_bib46","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1182\/blood-2011-04-350017","article-title":"Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children\u2019s Oncology Group Study A2971","volume":"118","author":"Gamis","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cppeds.2016.04.003_bib47","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2007-01-069542","article-title":"Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome","volume":"110","author":"Pine","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cppeds.2016.04.003_bib48","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.cppeds.2016.04.003_bib49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/asheducation-2004.1.80","article-title":"The molecular basis of leukemia","author":"Gilliland","year":"2004","journal-title":"Hematology"},{"issue":"8","key":"10.1016\/j.cppeds.2016.04.003_bib50","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2002-10-3062","article-title":"Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML)","volume":"101","author":"Guan","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cppeds.2016.04.003_bib51","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/blood-2007-02-076604","article-title":"The incidence and clinical significance of nucleophosmin mutations in childhood AML","volume":"110","author":"Brown","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cppeds.2016.04.003_bib52","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/10428190500051042","article-title":"Treatment-related myelodysplastic syndrome\/acute myeloid leukemia in survivors of childhood cancer\u2014an update","volume":"46","author":"Barnard","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.cppeds.2016.04.003_bib53","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.1993.11.6.1039","article-title":"Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation","volume":"11","author":"Sandoval","year":"1993","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cppeds.2016.04.003_bib54","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2141.1986.tb07533.x","article-title":"Acute myeloid leukaemia in childhood: clinical features and prognosis","volume":"63","author":"Chessells","year":"1986","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib55","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/sj.leu.2403188","article-title":"Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93","volume":"18","author":"Lehrnbecher","year":"2004","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.cppeds.2016.04.003_bib56","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.23581","article-title":"Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis","volume":"113","author":"Inaba","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.cppeds.2016.04.003_bib57","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/10428190290012056","article-title":"Isolated myelosarcoma in children\u2014update and review","volume":"43","author":"Reinhardt","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.cppeds.2016.04.003_bib58","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.cppeds.2016.04.003_bib59","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1182\/blood-2012-02-392506","article-title":"How I treat pediatric acute myeloid leukemia","volume":"119","author":"Rubnitz","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cppeds.2016.04.003_bib60","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children\u2019s Oncology Group","volume":"120","author":"Loken","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.cppeds.2016.04.003_bib61","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cppeds.2016.04.003_bib62","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.24432","article-title":"Children\u2019s Oncology Group\u2019s 2013 blueprint for research: acute myeloid leukemia","volume":"60","author":"Gamis","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib63","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/pbc.21157","article-title":"Toxicity and outcome of children with treatment related acute myeloid leukemia","volume":"50","author":"Tabori","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.cppeds.2016.04.003_bib64","doi-asserted-by":"crossref","unstructured":"Taub JW, Berman JN, Hitzler JK et al. Improvement in treatment outcome and identification of a new prognostic parameter in Down syndrome acute myeloid leukemia (DS-AML): results of the Children\u2019s Oncology Group (COG) Phase III AAML0431 Trial. 55th Annual ASH Meeting and Exposition. San Francisco, CA, USA; 2014.","DOI":"10.1182\/blood.V124.21.278.278"},{"issue":"2","key":"10.1016\/j.cppeds.2016.04.003_bib65","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/blood-2004-05-1971","article-title":"GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children","volume":"106","author":"Testi","year":"2005","journal-title":"Blood"},{"issue":"49","key":"10.1016\/j.cppeds.2016.04.003_bib66","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/sj.onc.1204763","article-title":"All trans retinoic acid in acute promyelocytic leukemia","volume":"20","author":"Degos","year":"2001","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.cppeds.2016.04.003_bib67","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1073\/pnas.94.8.3978","article-title":"Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia","volume":"94","author":"Zhu","year":"1997","journal-title":"Proc Ntl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.cppeds.2016.04.003_bib68","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1084\/jem.189.7.1043","article-title":"Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia","volume":"189","author":"Lallemand-Breitenbach","year":"1999","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.cppeds.2016.04.003_bib69","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2141.2007.06504.x","article-title":"The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells","volume":"136","author":"Stapnes","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.cppeds.2016.04.003_bib70","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/pbc.23394","article-title":"Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia","volume":"59","author":"Watt","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.cppeds.2016.04.003_bib71","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1517\/13543784.2013.758712","article-title":"Lenalidomide as a novel treatment of acute myeloid leukemia","volume":"22","author":"Chen","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"issue":"27","key":"10.1016\/j.cppeds.2016.04.003_bib72","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib73","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1542\/peds.2004-2473","article-title":"Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia","volume":"116","author":"Millot","year":"2005","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib74","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2141.1997.d01-1982.x","article-title":"Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period","volume":"96","author":"Savage","year":"1997","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.cppeds.2016.04.003_bib75","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib76","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/asheducation-2010.1.368","article-title":"Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation","author":"Suttorp","year":"2010","journal-title":"Hematology, The Education Program of the American Society of Hematology"},{"issue":"4","key":"10.1016\/j.cppeds.2016.04.003_bib77","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1046\/j.1365-2141.1999.01645.x","article-title":"A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada","volume":"106","author":"Hasle","year":"1999","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.cppeds.2016.04.003_bib78","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/bjc.1994.431","article-title":"Neurofibromatosis and childhood leukaemia\/lymphoma: a population-based UKCCSG study","volume":"70","author":"Stiller","year":"1994","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.cppeds.2016.04.003_bib79","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0022-3476(97)70273-7","article-title":"Occurrence of myeloproliferative disorder in patients with Noonan syndrome","volume":"130","author":"Bader-Meunier","year":"1997","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.cppeds.2016.04.003_bib80","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-2141.2007.06958.x","article-title":"Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options","volume":"140","author":"Niemeyer","year":"2008","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.cppeds.2016.04.003_bib81","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood-2014-08-550483","article-title":"How I treat juvenile myelomonocytic leukemia","volume":"125","author":"Locatelli","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cppeds.2016.04.003_bib82","first-page":"3534","article-title":"Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)","volume":"89","author":"Niemeyer","year":"1997","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.cppeds.2016.04.003_bib83","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1182\/blood-2013-01-478412","article-title":"Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia","volume":"121","author":"Gandre-Babbe","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.cppeds.2016.04.003_bib84","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1182\/blood-2007-10-117150","article-title":"Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study","volume":"111","author":"Mody","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.cppeds.2016.04.003_bib85","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1182\/blood.V99.12.4257","article-title":"Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983","volume":"99","author":"Bhatia","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cppeds.2016.04.003_bib86","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2015-02-627414","article-title":"Chemotherapy-only treatment effects on long-term neurocognitive functioning in childhood ALL survivors: a review and meta-analysis","volume":"126","author":"Iyer","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cppeds.2016.04.003_bib87","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2141.2003.04499.x","article-title":"Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence","volume":"122","author":"Robison","year":"2003","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.cppeds.2016.04.003_bib88","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0022-3476(85)80343-7","article-title":"Long-term neuropsychologic sequelae of childhood leukemia: correlation with CT brain scan abnormalities","volume":"106","author":"Brouwers","year":"1985","journal-title":"J Pediatr"},{"issue":"7","key":"10.1016\/j.cppeds.2016.04.003_bib89","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/1097-0142(19921001)70:7<1997::AID-CNCR2820700732>3.0.CO;2-G","article-title":"Nuclear magnetic resonance abnormalities of the cerebral white matter in children with acute lymphoblastic leukemia and malignant lymphoma during and after central nervous system prophylactic treatment with intrathecal methotrexate","volume":"70","author":"Asato","year":"1992","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.cppeds.2016.04.003_bib90","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJM197804132981504","article-title":"Abnormal CT scans of the brain in asymptomatic children with acute lymphocytic leukemia after prophylactic treatment of the central nervous system with radiation and intrathecal chemotherapy","volume":"298","author":"Peylan-Ramu","year":"1978","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cppeds.2016.04.003_bib91","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/pbc.21869","article-title":"Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: a critical review of the literature","volume":"52","author":"Buizer","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib92","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/pbc.20860","article-title":"A meta-analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia","volume":"49","author":"Campbell","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.cppeds.2016.04.003_bib93","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3324\/haematol.2012.081265","article-title":"Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood","volume":"98","author":"Girard","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib94","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.1997.15.1.61","article-title":"Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity","volume":"15","author":"Sorensen","year":"1997","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.cppeds.2016.04.003_bib95","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1210\/jc.2009-0060","article-title":"Effect of childhood acute lymphoblastic leukemia therapy on spermatogonia populations and future fertility","volume":"94","author":"Nurmio","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.cppeds.2016.04.003_bib96","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/mpo.2950190603","article-title":"Reproduction following treatment for childhood leukemia: a population-based prospective cohort study of fertility and offspring","volume":"19","author":"Nygaard","year":"1991","journal-title":"Med Pediatr Oncol"},{"issue":"3","key":"10.1016\/j.cppeds.2016.04.003_bib97","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2307\/3574084","article-title":"Effect of graded doses of ionizing radiation on the human testis","volume":"59","author":"Rowley","year":"1974","journal-title":"Radiat Res"},{"issue":"1","key":"10.1016\/j.cppeds.2016.04.003_bib98","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/humrep\/deg016","article-title":"The radiosensitivity of the human oocyte","volume":"18","author":"Wallace","year":"2003","journal-title":"Hum Reprod"},{"issue":"23","key":"10.1016\/j.cppeds.2016.04.003_bib99","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber","year":"1948","journal-title":"N Engl J Med"}],"container-title":["Current Problems in Pediatric and Adolescent Health Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1538544216300153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1538544216300153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T18:51:56Z","timestamp":1600714316000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538544216300153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":99,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1538544216300153"],"URL":"https:\/\/doi.org\/10.1016\/j.cppeds.2016.04.003","relation":{},"ISSN":["1538-5442"],"issn-type":[{"value":"1538-5442","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress and Prospects in Pediatric Leukemia","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Pediatric and Adolescent Health Care","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.cppeds.2016.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}